MONTPELLIER, France–(BUSINESS WIRE)–Regulatory News: NFL BIOSCIENCES (Euronext Growth Paris – FR0014003XT0 – ALNFL), (Euronext Growth Paris – FR0014003XT0 – ALNFL), a biopharmaceutical company developing innovative botanical drugs for the treatment of addictions, today announces having received convergent and constructive scientific advice from several regulatory agencies, including the Belgian, Dutch, UK, and German authorities, as well as the U.S. FDA, as part of the development of NFL-101.